Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/17/2025 | $20.00 | Buy | H.C. Wainwright |
SC 13D - ACTUATE THERAPEUTICS, INC. (0001652935) (Subject)
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
Initial Data from this Phase 2 Trial Demonstrates Early Evidence of Clinical Activity of Elraglusib (9-ING-41) in Combination with FOLFIRINOX and Losartan in Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)The Final Results from the Trial are Anticipated in 2026 CHICAGO and FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced the completion of patient enrollment in the ongoing Phase 2 trial of F
CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will participate in the following upcoming investor conferences: BIO CEO & Investor ConferenceFormat: "IPO Class of 2024 Panel" and one-on-one meetingsDate: February 10, 2025Location: New York, NY Registered conference attendees may schedule one-on-one meetings with Actua
H.C. Wainwright initiated coverage of Actuate Therapeutics with a rating of Buy and set a new price target of $20.00
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
424B3 - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
D - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
DEFA14A - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)
4 - ACTUATE THERAPEUTICS, INC. (0001652935) (Issuer)